Cooper Companies Stock (NASDAQ:COO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$82.11

52W Range

$61.78 - $100.24

50D Avg

$73.03

200D Avg

$74.68

Market Cap

$16.35B

Avg Vol (3M)

$2.90M

Beta

1.05

Div Yield

-

COO Company Profile


The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

16,000

IPO Date

Jan 21, 1983

Website

COO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceOct 25Oct 24Oct 23
Coopervision Segment$2.74B$2.61B$2.42B
Coopersurgical Segment$1.35B$1.29B$1.17B
CooperSurgical Segment--$1.17B
CooperVision Segment--$2.42B

Fiscal year ends in Oct 25 | Currency in USD

COO Financial Summary


Oct 25Oct 24Oct 23
Revenue$4.09B$3.90B$3.59B
Operating Income$682.90M$705.70M$533.10M
Net Income$374.90M$392.30M$294.20M
EBITDA$666.50M$1.07B$885.90M
Basic EPS$1.87$1.97$1.49
Diluted EPS$1.87$1.96$1.48

Fiscal year ends in Oct 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Dec 04, 25 | 5:00 PM
Q3 25Aug 27, 25 | 5:00 PM
Q2 25May 29, 25 | 5:00 PM

Peer Comparison


TickerCompany
SNNSmith & Nephew plc
FMSFresenius Medical Care AG & Co. KGaA
TEMTempus AI, Inc.
HOLXHologic, Inc.
ICLRICON Public Limited Company
NBIXNeurocrine Biosciences, Inc.
UHSUniversal Health Services, Inc.
SMMTSummit Therapeutics Inc.
SOLVSolventum Corporation
DOCSDoximity, Inc.